NASDAQ:REPH - Recro Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.81 +0.02 (+0.26 %)
(As of 01/15/2019 04:00 PM ET)
Previous Close$7.79
Today's Range$7.79 - $8.02
52-Week Range$4.78 - $13.05
Volume67,692 shs
Average Volume136,850 shs
Market Capitalization$167.95 million
P/E Ratio-3.92
Dividend YieldN/A
Beta-0.52
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Current Ratio1.36
Quick Ratio1.16

Price-To-Earnings

Sales & Book Value

Annual Sales$71.83 million
Price / Sales2.34
Price / Cash FlowN/A
Book Value$1.51 per share
Price / Book5.17

Profitability

Net Income$-50,080,000.00
Net Margins-79.42%
Return on Assets-27.96%

Miscellaneous

Employees256
Market Cap$167.95 million
OptionableOptionable

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) issued its quarterly earnings data on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.03. The specialty pharmaceutical company had revenue of $18.28 million for the quarter, compared to the consensus estimate of $16.77 million. Recro Pharma had a negative return on equity of 220.42% and a negative net margin of 79.42%. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Recro Pharma.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75-75 million, compared to the consensus revenue estimate of $73.46 million.

What price target have analysts set for REPH?

7 equities research analysts have issued 1-year price targets for Recro Pharma's stock. Their predictions range from $9.00 to $19.00. On average, they anticipate Recro Pharma's share price to reach $13.80 in the next twelve months. This suggests a possible upside of 76.7% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

News coverage about REPH stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Recro Pharma earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 59)
  • Dr. Stewart McCallum, Chief Medical Officer (Age 52)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 41)
  • Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53)

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $7.81.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $167.95 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel